Emerging Trends to Reshape the Influenza Treatment Market: Companies Expand Influenza Treatment Options With Single-Dose Oral Medicines as a Key Influencer

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Influenza Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for influenza treatment has been progressively expanding in the past few years. It is forecasted to rise from a value of $6.6 billion in 2024 to $6.9 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 4.5%. The surge observed in the historic period can be traced back to factors such as the increase in annual influenza cases, boosted government financial support for influenza research and readiness initiatives, campaigns propagating public awareness about vaccination, the setup of global influenza tracking systems, and the development in healthcare facilities.

Influenza Treatment Market Size Forecast: What's the Projected Valuation by 2029?
Over the forthcoming years, the market size of influenza treatment is projected to undergo consistent growth, expanding to $8.16 billion in 2029 with a 4.3% compound annual growth rate (CAGR). The introduction of novel antiviral medications and treatment options, broadening vaccination initiatives, continued enhancement and growth of healthcare systems, a rise in the aging population, and the emergence of new treatments contribute to this predicted growth. Key trends in this forecast period consist of advancements towards producing universal vaccines, breakthroughs in vaccine delivery methodologies, the incorporation of AI and big data, strides in personalized healthcare, and elevated cooperation among pharmaceutical firms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

What Are the Drivers Transforming the Influenza Treatment Market?
The rise in instances of contagious respiratory diseases is anticipated to propel the influenza treatment market. These illnesses like influenza, measles, or respiratory syncytial virus (RSV) infections are infectious diseases, spread through interaction with a contaminated person or their bodily fluids, infected surfaces, or objects. Conditions promoting the expansion of these respiratory diseases include higher populations, insufficient healthcare structures, misuse of antibiotics, and ease of international travel. Influenza treatment includes antiviral medications and vaccines that treat a range of contagious respiratory illnesses including flu, COVID-19, and other respiratory viruses. For example, in September 2023, the US-based Centers for Disease Control and Prevention (CDC) reported that the rate of hospitalizations linked to RSV (Respiratory Syncytial Virus) skyrocketed from 2 hospitalizations per 100,000 people for the week ending August 5, 2023, to 7 hospitalizations per 100,000 people for the week concluding on August 19, 2023. As such, the rise in instances of contagious respiratory diseases continues to push the growth of the influenza treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15832&type=smp

What Long-Term Trends Will Define the Future of the Influenza Treatment Market?
Significant players in the influenza treatment market are striving to broaden their selection of products through the introduction of innovative solutions like single-dose oral medication for flu treatment. These aim to increase patient adherence, enhance the results of the treatment, and claim a greater segment of the market. A single-dose oral medicine is a medication engineered to treat influenza (flu) in a single oral dose, thereby simplifying the treatment process. For example, in August 2022, Genentech Inc., an American biotech firm, declared that the U.S. Food and Drug Administration (FDA) approved Xofluza (Baloxavir Marboxil). Xofluza is the first and only single-dose oral medication to provide an efficient and practical method for managing acute uncomplicated flu in children aged from five to under 12 who have exhibited symptoms for less than 48 hours and other respiratory viruses.

Which Segments in the Influenza Treatment Market Offer the Most Profit Potential?
The influenza treatment market covered in this report is segmented -

1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:
1) By Peramivir: Intravenous Peramivir, Peramivir Injection
2) By Zanamivir: Inhaled Zanamivir, Zanamivir Diskhaler
3) By Oseltamivir Phosphate: Oseltamivir Capsules, Oseltamivir Oral Suspension
4) By Baloxavir Marboxil: Baloxavir Tablets, Baloxavir Granules For Oral Suspension
5) Other Products: Rimantadine, Amantadine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15832&type=smp

Which Firms Dominate the Influenza Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

Which Regions Offer the Highest Growth Potential in the Influenza Treatment Market?
North America was the largest region in the influenza treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15832

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.